2. Signaling Pathways
  3. Immunology/Inflammation
  4. NO Synthase

NO Synthase

Nitric oxide synthases; NOS

NO Synthase

Related Products

PDF 1.66 MB

Nitric oxide synthases (NOSs) are a family of enzymes catalyzing the production of nitric oxide (NO) from L-arginine. NO synthases catalyze the oxidation of L-arginine to NO and L-citrulline. Mammals contain three NOS isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). NO produced from these different NOS isoforms is involved in a wide range of physiologic functions in the nervous, immune, and cardiovascular systems. Unregulated NO production can lead to pathologic conditions such as stroke, inflammation, and hypertension. Therefore, the control of NOS activity by isoform selective NOS inhibitors has great potential for therapeutic treatments of NO-related diseases.

NO Synthase Isoform Specific Products:

NO Synthase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N3364
    Lucidone
    		Inhibitor
    Lucidone, an anti-inflammatory agent that can be isolated from the fruit of Lindera erythrocarpa Makino. Lucidone inhibits LPS-induced NO and PGE2 production in RAW 264.7 mouse macrophages. Lucidone also decreases TNF-α secretion, iNOS and COX-2 expression. Lucidone prevents NF-κB translocation and inhibits JNK and p38MAPK signals. Lucidone also has inhibitory activity against Dengue virus (DENV) (EC50=25 μM).
    Lucidone
  • HY-P10586
    Macrophage-activating lipopeptide 2
    		Inducer
    Macrophage-activating lipopeptide 2 (MALP-2) is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 can enhance endothelial nitric oxide synthase (eNOS) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 can enhance endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL).
    Macrophage-activating lipopeptide 2
  • HY-172977
    FGA139
    		Inhibitor
    FGA139 is a cysteine proteases inhibitor with IC50 values of 4.98/3.14 μM for cathepsin B/L. FGA139 reduces LPS-induced NO production in RAW264.7 cells and tumor necrosis factor (TNFα) levels in microglia, and has anti-oxidative stress and anti-inflammatory activities. FGA139 promotes the secretion of neuroprotective metabolites purine and linoleic acid by LPS-stimulated microglia. FGA139 can be used in neuroinflammatory diseases research.
    FGA139
  • HY-N12570
    Isoarundinin I
    Isoarundinin I is a stilbene compound that can be isolated from Arundinu bambusifolia.
    Isoarundinin I
  • HY-151188
    DHU-Se1
    		Inhibitor
    DHU-Se1 is a potent anti-inflammatory agent. DHU-Se1 can stimulate macrophages to release the reactive selenium compound and reduce the expression of cellular inflammatory factors (eg: iNOS and TNF-α). DHU-Se1 alleviate the process of inflammation by blocking the polarization of macrophages from M0 to M1.
    DHU-Se1
  • HY-N3392
    Lethedoside A
    		Inhibitor
    Lethedoside A is a natural flavonoid that shows inhibitory activity for LPS-induced NO production in RAW 264.7 cells.
    Lethedoside A
  • HY-W751179
    Midostaurin-13C6
    Midostaurin-13C6 (PKC412-13C6) is the 13C-labeled Midostaurin (HY-10230). Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM. Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects.
    Midostaurin-<sup>13</sup>C<sub>6</sub>
  • HY-174807
    NPB-1575
    		Inhibitor
    NPB-1575 is a potent, orally active and brain-penetrant anti-inflammatory agent. NPB-1575 mitigates neuroinflammation and resists ferroptosis by activating the IRS2/Nrf2/NF-κB axis. NPB-1575 shows protective effect against cerebral ischemic injury and improves the neurological functional prognosis. NPB-1575 can be used for the study of ischemic stroke.
    NPB-1575
  • HY-155820
    Anti-inflammatory agent 54
    		Inhibitor
    Anti-inflammatory agent 54 (compound 9c) is a derivative of Coixol and has anti-inflammatory activity. Anti-inflammatory agent 54 inhibits the NF-κB pathway and downregulates the expression of iNOS, TNF-α, IL-6 and IL-1β. Anti-inflammatory agent 54 inhibits LPS-induced nitric oxide (NO) production in RAW264.7 macrophages (IC50: 2.4 μM) and exerts in vivo anti-inflammatory activity in a mouse auricular edema model.
    Anti-inflammatory agent 54
  • HY-113216S
    Asymmetric dimethylarginine-d7 hydrochloride hydrate
    Asymmetric dimethylarginine-d7 (hydrochloride hydrate) is the deuterium labeled Asymmetric dimethylarginine. Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS), and functions as a marker of endothelial dysfunction in a num
    Asymmetric dimethylarginine-d<sub>7</sub> hydrochloride hydrate
  • HY-N2989
    3-O-Acetyl-16α-hydroxydehydrotrametenolic acid
    		Inhibitor
    3-O-Acetyl-16α-hydroxydehydrotrametenolic acid, an anti-inflammatory triterpenoid, inhibits NO production and iNOS expression in LPS-stimulated Raw264.7 cells.
    3-O-Acetyl-16α-hydroxydehydrotrametenolic acid
  • HY-141411
    (Rac)-Zevaquenabant
    		Inhibitor 99.20%
    (Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB1R)/iNOS antagonist, with a Ki of 5.7 nM for CB1R. (Rac)-Zevaquenabant is potential for the research of liver fibrosis.
    (Rac)-Zevaquenabant
  • HY-U00432
    S-MTC
    		Inhibitor
    S-MTC is a selective type I nitric oxide synthase (NOS) inhibitor.
    S-MTC
  • HY-Y0148R
    10-Hydroxydecanoic acid (Standard)
    		Inhibitor
    10-Hydroxydecanoic acid (Standard) is the analytical standard of 10-Hydroxydecanoic acid. This product is intended for research and analytical applications. 10-Hydroxydecanoic acid (10-HDAA) is a saturated fatty acid derived from 10-hydroxy-trans-2-decenoic acid, which can be isolated from royal jelly. 10-Hydroxydecanoic acid exhibits various biological activities, including anti-inflammatory, insecticidal, anti-malarial, and anti-Leishmania properties, as well as enhancing antigen-specific immune responses. The anti-inflammatory effects of 10-Hydroxydecanoic acid are primarily mediated by inhibiting the activation of NF-κB and the translation of interferon regulatory factor 1 (IRF-1), which reduces the production of interleukin 6 (IL-6) and nitric oxide (NO) in inflammatory cells. Additionally, 10-Hydroxydecanoic acid alleviates neuroinflammatory responses through the p53-autophagy pathway and the p53-NLRP3 pathway. Finally, 10-Hydroxydecanoic acid enhances antigen-specific immune responses by promoting the effective uptake of antigens by microfold cells[1][2][3][4][5].
    10-Hydroxydecanoic acid (Standard)
  • HY-170236
    nNOS-IN-5
    		Inhibitor
    nNOS-IN-5 (Compound 9) is a potent human neuronal NOS (nNOS) inhibitor (Ki = 22 nM). nNOS-IN-5 exhibits excellent selectivity, with a 900-fold preference for human nNOS over human endothelial NOS (eNOS). nNOS-IN-5 can be used for neurodegenerative diseases study, such as Alzheimer's disease and Parkinson’s disease.
    nNOS-IN-5
  • HY-100986B
    L-NIO
    		Inhibitor
    L-NIO is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with Kis of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively. L-NIO induces a consistentfocal ischemic infarctin rats.
    L-NIO
  • HY-18252S1
    Avanafil-13C5,15N,d2
    		Inhibitor
    Avanafil-13C5,15N,d2 is 15N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
    Avanafil-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N,d<sub>2</sub>
  • HY-153762
    COX-2-IN-32
    		Inhibitor
    COX-2-IN-32 (Compound 2f) is an iNOS and COX-2 inhibitor. COX-2-IN-32 decreases the expression of NF-κB. COX-2-IN-32 has anti-inflammatory activity by inhibits NO production in LPS-induced RAW264.7 macrophages (IC50: 11.2 μM).
    COX-2-IN-32
  • HY-N8427
    Bisacurone
    		Inhibitor
    Bisacurone is a natural terpenoid, exhibits inhibitory activities on LPS-induced NO production with an IC50 of 29.8 μM.
    Bisacurone
  • HY-N0455AS3
    L-Arginine-1-13C hydrochloride
    		Activator 99.60%
    L-Arginine-1-13C (hydrochloride) is the 13C-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
    L-Arginine-1-<sup>13</sup>C hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity
NO Synthase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.